Abbott Laboratories Corporation

Biogen Ma Inc.

Eisai R&d Management Co., Ltd.

Biogen Idec Ma Inc.

Abbvie Inc.

Boigen Ma Inc.

Guo Zhu Zheng

Gnanasambandam Kumaravel

Kevin Guckian

Richard Dana Caldwell

Edward Yin-Shiang Lin

Jermaine Thomas

Bin Ma

Arthur G Taveras

Xiaogao Liu

Chih-hung Lee

John R Koenig

Sean Colm Turner

Arthur Gomtsyan

Daniel M Scott

Wen-Cherng Lee

Erol K Bayburt

Robert G Schmidt

Zhan Shi

Tammie K White

John JianShi Wang

Sha Mi

Richard J Perner

Stanley DiDomenico

Marlon D Cowart

Chen Zhao

Irene I Drizin

Minghua Sun

Peter G Smith

Ming-Hong Hao

Yoshihiko Kotake

Gregg F Keaney

Kazunobu Kira

Parcharee Tivitmahaisoon

Sudeep Prajapati

Norio Murai

Baudouin Gerard

Xiang Liu

Satoshi Nagao

Masayuki Miyano

Kenzo Arai

Nicholas C Gearhart

Regina Mikie Kanada Sonobe

Mark G Bock

Lawrence A Black

Atsushi Endo

Susanta Samajdar

Brian S Brown

Ping Zhu

Lawrence Kolaczkowski

Silvia Buonamici

Lihua Yu

Ermira Pazolli

Robert J Gregg

Manav Korpal

Kian Huat Lim

Eunice Sun Park

Michael P Thomas

Betty Chan

Vijay Kumar Nyavanandi

Xiaoling Puyang

Anthony Ralph Haight

Geoff G Z Zhang

Andrew O Stewart

Rodger F Henry

David M Barnes

Dominic J Reynolds

Ahmad Y Sheikh

Steven J Wittenberger

Andrew Cook

Sou-Jen Chang

Marta Nevalainen

Arani Chanda

Xiaochun Lou

Jason T Lowe

James Palacino

Daniel P Larson

Shelby Ellery

Michael G Fickes

Lisa A Marcaurelle

Meiqun Jiang

Richard A Perner

Morgan Welzel O'shea

Tuoping Luo

Ma Bin

Peter Gerard Smith

Regina Mikie Kanada Sonabe

Chih-Hung Lee

Stanley Didomenico

Arthur R Gomtsyan

Regina Kanada Sonobe

Sundeep Prajapati

Kevin M Guckian

The present disclosure provides novel pladienolide compounds, pharmaceutical compositions containing such compounds, and methods for using the compounds as therapeutic agents. These compounds may be useful in the treatment of cancers, particularly cancers in which agents that target the spliceosome and mutations therein are known to be useful. Also provided herein are methods of treating cancers by administering at least one compound disclosed herein and at least one additional therapy.

Certain pladienolide compounds and methods of use

The present invention provides compounds of formula (I) or (II) or a pharmaceutically acceptable salt thereof and their use in modulating the activity of S1P) receptors. Also provided is a pharmaceutical composition comprising the compounds of formula (I) or (II) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient or carrier.

S1P modulating agents

Disclosed herein are compounds, or pharmaceutically acceptable salts thereof, and methods of using the compounds for treating breast cancer by administration to a subject in need thereof a therapeutically effective amount of the compounds or pharmaceutically acceptable salts thereof. The breast cancer may be an ER-positive breast cancer and/or the subject in need of treatment may express a mutant ER-&#x3b1; protein.

Tetrasubstituted alkene compounds and their use

The present disclosure provides a novel solid state form of pladienolide pyridine compounds having Formula I, compositions comprising at least one such solid state form, and methods of preparation and use and the same. The novel solid state form of pladienolide pyridine compounds may be useful in the treatment of cancer, such as, for example, cancers in which agents that target the spliceosome and mutations therein are known to be useful. 

Crystalline form of (2S,3S,6S,7R,10R,E)-7,10-dihydroxy-3,7-dimethyl-12-oxo-2-((R,2E,4E)-6-(piridin-2-yl)hepta-2,4-dien-2-yl)oxacyclododec-4-en-6-yl-4-methylpiperazine-1-carboxylate and methods of use thereof

Compounds of formula (I) or (II) can modulate the activity of S1P receptors.

SIP modulating agents

Compounds that have agonist activity at one or more of the S1P receptors are provided. The compounds are sphin-gosine analogs that, after phosphorylation, can behave as agonists at S1P receptors.

Bicyclic aryl sphingosine 1-phosphate analogs

Compounds that have agonist activity at one or more of the S1P receptors are provided. The compounds are sphingosine analogs that, after phosphorylation, can behave as agonists at S1P receptors.

Heterobicyclic sphingosine 1-phosphate analogs

The present invention provides compounds of formula (I) or (II) or a pharmaceutically acceptable salt thereof and their use in modulating the activity of S1P receptors. Also provided is a pharmaceutical composition comprising the compounds of formula (I) or (II) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient or carrier.

The present invention provides novel pladienolide pyridine compounds, pharmaceutical compositions containing such compounds, and methods for using the compounds as therapeutic agents. These compounds may be useful in the treatment of cancer, particularly cancers in which agents that target the spliceosome and mutations therein are known to be useful.

Pladienolide pyridine compounds and methods of use

Compounds of formula (I) or (II) can modulate the activity of SIP receptors.

Growing community of inventors

Lexington, MA, United States of America

Guo Zhu Zheng